Taro Pharmaceutical Industries Ltd. Receives FDA Approval for Imiquimod Cream, 5%

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro,” or the “Company,” Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (ANDA) for Imiquimod Cream, 5% (“imiquimod cream”).

MORE ON THIS TOPIC